Bead Array–Based microRNA Expression Profiling of Peripheral Blood and the Impact of Different RNA Isolation Approaches

Andrea Gaarz,* Svenja Debey-Pascher,† Sabine Classen,* Daniela Eggle,‡ Birgit Gathof,‡ Jing Chen,§ Jian-Bing Fan,§ Thorsten Voss,¶ Joachim L. Schultze,* and Andrea Staratschek-Jox*

From Life and Medical Sciences (LIMES), Genomics and Immunoregulation,* University of Bonn, Bonn Germany; Department of Internal Medicine I, MTBITI, University of Cologne, Cologne Germany; the Institute for Transfusion Medicine;† University of Cologne, Cologne, Germany; Illumina, Inc.;‡ San Diego, California; and QIAGEN GmbH.§ Diagnostic Sample Preparation & Stabilization, R&D Department, Hilden, Germany

Blood-based mRNA expression profiling has already become an important issue in clinical applications. More recently, the characterization of the small RNA transcriptome offers additional avenues for diagnostic approaches. However, when applying miRNA expression profiling in routine clinical settings, the method of RNA preservation and the manner of RNA extraction as well as the reliability of the miRNA profiling procedure have to be carefully considered. Here we evaluate a recently introduced bead array–based technology as a robust method for the generation of blood-based human miRNA expression profiles. Importantly the comparison of different RNA extraction strategies resulted in dissimilar profiles depending on the RNA extraction method as well as on the underlying source. Expression profiles obtained from peripheral mononuclear cells (PBMCs) substantially differed from those of whole blood samples, whereby both sources per se yielded reproducible and reliable results. Expression profiles were also distinct when using either fresh or frozen PBMCs. Moreover RNA size fractioning resulted in discriminative miRNA expression profiles compared with total RNA based profiles. This study outlines important steps toward the establishment of a robust strategy for blood-based miRNA profiling and provides a reliable strategy for its implementation in routine handling for diagnostic purposes. (J Mol Diagn 2010, 12:000–000; DOI: 10.2353/jmoldx.2010.090116)

Gene expression profiling has already been widely accepted as a powerful tool to investigate the transcriptome of a given source to describe disease-specific signatures as well as to identify pathogenetic relevant genes on its deregulated transcription. In peripheral blood, gene expression profiling is used to characterize specific signatures for differential diagnosis of hematological neoplasias such as leukemia and also to associate specific blood-based signatures to the occurrence of a variety of other diseases such as infectious disease, cardiovascular disease, autoimmune disease, and cancer. In general, peripheral blood represents an archive of all ongoing processes in an organism and is easily accessible in clinical settings. Therefore, its use for diagnostic and prognostic applications is widely established. However, the analysis of the blood-derived RNA transcriptome requires serial mandatory preconditions. Most important, the RNA should be stabilized immediately after blood taken because even short-time storage of blood cells either at room temperature or under freezing conditions introduces dramatic changes at least to the mRNA composition.

More recently, the discovery of noncoding small RNA transcripts including microRNA (miRNA) has opened new promising avenues for diagnostic implementations of transcriptomics. miRNAs represent a family of functional RNAs of 19 to 23 nucleotides (nt) cleaved from 60- to 110-nt hairpin precursor microRNA (pre miRNA) by Dicer, which is a RNase III enzyme. Pre miRNAs in turn are processed from the primary transcript (pri RNA) by RNase III Drosha. The regulatory role of miRNAs is conducted by translational repression or degradation of specific target mRNAs. MiRNAs exert important roles in developmental

Supported in part by a Sofja-Kovalevskaja award from the Alexander von Humboldt-Foundation (to J.L.S.) and a grant from the Deutsche Krebshilfe (to S.D.-P.).

A.G. and S.D.-P. contributed equally to this study.

Current address of D.E.: Pharma Research Scientific Informatics, Roche Diagnostics, Penzberg, Germany.

Present address of the author Sabine Classen: Miltenyi Biotech GmbH, Genomics Service Department, Bergisch Gladbach Germany.

Jing Chen and Jian-Bing Fan are employees and stockholders of Illumina Inc.

Accepted for publication December 14, 2009.

Supplemental material for this article can be found on http://jmd.amjpathol.org.

Address reprint requests to Priv. Doz. Dr. Andrea Staratschek-Jox or Prof. Dr. Joachim L. Schultze, LIMES (Life and Medical Sciences Bonn), Genomics and Immunoregulation, University of Bonn, Carl Tres Str. 31, D-53115 Bonn, Germany. E-mail: staratschek-jox@uni-bonn.de or j.schultze@uni-bonn.de.
processes, cell proliferation, hematopoietic differentiation, regulation of lymphoid subset lineage differentiation, oncogenic transformation, and apoptosis.\(^7\) Many reports have already described altered expression of miRNAs in cancer samples compared with normal tissues including breast cancer,\(^6\) sarcomas,\(^9\) leukemias,\(^10,11\) lymphomas,\(^12\) prostate cancer,\(^13\) and autoimmune diseases.\(^\)\(^14\) These data indicate that analyzing miRNA expression can be used to define tumor subtypes, to identify new clinical and prognostic markers, and to classify human cancer entities. One important result of these efforts is that expression profiling derived from miRNAs can be used for cancer classification with more accuracy than mRNA expression profiles.\(^15\) Interestingly, miRNAs were reported to be actively secreted by tumor cells through the formation of microvesicles.\(^16,17\) Such microvesicles can be traced back in peripheral blood,\(^17\) leading to the assumption that peripheral blood might be a perfect source to monitor tumor-associated miRNA expression signatures for early diagnosis and prediction of therapeutic outcome. Subsequently, most recently blood-based disease specific miRNA signatures were identified in lung cancer patients,\(^18\) patients suffering from multiple sclerosis,\(^19\) as well as in young stroke patients.\(^20\)

Until now, several methods have been developed to allow miRNA identification and quantification including cloning approaches,\(^3,21\) Northern blots,\(^22,23\) real-time PCR,\(^24\) bead-based flow cytometric approaches,\(^15,25\) and customized microarray-based methods.\(^26–28\) Technical issues regarding high-throughput miRNA expression profiling are discussed by various authors.\(^29,30\) With regard to peripheral blood, most of these studies were based on RNA extracted from either whole blood or extracted peripheral blood mononuclear cells (PBMCs).

More recently, a bead array–based assay was introduced comprising 735 human miRNAs allowing high-throughput expression profiling in a large number of samples.\(^31\) In the present study we evaluated this newly introduced array platform for miRNA expression profiling of peripheral blood. We assessed miRNA expression in whole blood as well as in separated PBMCs from healthy individuals. To evaluate the performance of the microarray we studied several aspects of technical reproducibility of the array results, the effect of different normalization approaches, and the influence of total RNA input amount on miRNA expression pattern results. Moreover, we addressed the question whether the enrichment of small RNA fraction in comparison with the use of total RNA improves results of miRNA expression profiling by, e.g., reducing nonspecific hybridization of longer miRNA precursors or interference of target miRNA molecules within the assay. The influence of cryopreservation of isolated PBMCs on miRNA expression profiles was investigated by comparing cryopreserved PBMCs to their directly lysed matched counterparts. Furthermore, we compared whole blood–derived PAXgene-based RNA to a TRIZOL-based approach using PBMCs. Microarray expression values were exemplary validated by qPCR of selected miRNA sequences. Our comprehensive miRNA screen is intended to serve as a reference for future studies assessing peripheral blood in the context of diagnosis and monitoring of certain diseases in clinical studies.

### Materials and Methods

#### Subject Information and Blood Sample Collection

Blood samples from 29 apparently healthy blood donors were collected in two cell preparation tubes with sodium citrate (CPT, Becton Dickinson, Heidelberg, Germany) after written informed consent had been obtained and after approval by the institutional review board. PBMCs were prepared following the manufacturer’s protocol.

To evaluate the influence of freezing cells in FCS with 10% (v/v) DMSO and storage in liquid nitrogen on miRNA stability, one portion of the freshly isolated PBMCs was lysed in TRIZOL\(^\)\(^*\) reagent (1 ml/1 \(10^7\) PBMCs, Invitrogen, Karlsruhe, Germany) and stored at \(-80^\circ\)C until further processing. The other portion of isolated PBMCs was resuspended in FCS with 10% (v/v) DMSO (1 ml/1 \(10^7\) PBMCs) and frozen at \(-80^\circ\)C. The next day frozen PBMCs were cryopreserved in liquid nitrogen for several days to weeks until further processing.

To analyze the difference between total RNA and less abundant low-molecular-weight (LMW) RNA, we collected blood samples from additional six healthy blood donors.

#### RNA Isolation

Total RNA from PBMCs stored in TRIZOL\(*\) was isolated according to the manufacturer’s protocol. For RNA isolation from PBMCs stored in liquid nitrogen, cells were removed from liquid nitrogen and transferred to a 37°C water bath until thawing. The thawed cell suspension was quickly transferred to 40 ml chilled RPMI medium and centrifuged at room temperature at 400 \(\times\) g for 10 minutes. Supernatant was removed, and PBMCs were washed once with 50 ml of room temperature RPMI and centrifuged at room temperature at 400 \(\times\) g for 10 minutes. Supernatant was completely removed, and cells were subsequently lysed in TRIZOL\(*\) reagent. RNA isolation was then performed according to the manufacturer’s protocol.

LMW RNA molecules were enriched using Invitrogen’s PureLink miRNA Isolation Kit (Invitrogen, Karlsruhe, Germany) according to manufacturer’s protocol. LMW RNAs (50 to 350 ng) were enriched from 1 to 2 µg of total RNAs, and 10 to 70 ng of the enriched RNAs were used for sample labeling and array hybridization.

For the comparison of isolation techniques blood samples from six apparently healthy blood donors were collected either in CPT or in PAXgene Blood RNA Tubes (PreAnalytiX, Hombrechtikon, Switzerland). PAXgene Blood RNA Tubes were stored at \(-20^\circ\)C until further processing. PBMCs were prepared from CPT following the manufacturer’s protocol and stored at \(-80^\circ\)C. Total RNA from PBMCs was isolated using TRIZOL\(*\) reagent (Invitrogen) according to the manufacturer’s protocol. RNA from PAXgene Blood RNA Tubes was isolated using the PAXgene Blood miRNA \(\beta\) Version extraction kit.
Analysis of RNA Samples

Total RNA was quantified by UV-spectroscopy at 260 nm. The quality of the isolated RNA samples was determined by measuring the A260/A280 ratio, and the integrity of the ribosomal 28s and 18s bands was determined by agarose-gel electrophoresis.

MiRNA-Microarray Procedure

MicroRNA expression profiling was performed using the MicroRNA Profiling β-Test Assay Kit for Sentrix Array Matrixes (Illumina, CA). This system is a modification of the high throughput gene expression profiling assay DASL® (cDNA-mediated annealing, selection, extension, and ligation), which provides a novel highly multiplexed assay and 96-sample Sentrix Array Matrix (SAM) readout.

The human miRNA panel used contained 735 miRNA-specific oligos detecting 470 well-annotated human miRNA sequences (miRBase: http://microrna.sanger.ac.uk/, version 9.1, date of accession 02/2007) and 265 potential miRNAs that were identified recently.

The miRNA microarray assays were generally performed with 500 ng total RNA if not otherwise stated. All steps were performed according to the manufacturer’s protocol. In brief, in a first step input RNA is polyadenylated and converted to cDNA using a biotinylated oligo-dT primer with a universal PCR sequence at its 5’ end. In a second step the biotinylated cDNA is annealed to the 735 miRNA-specific oligos. The mixture is bound to streptavidin-conjugated paramagnetic particles to select cDNA/oligo complexes. After washing out mis-hybridized and non-hybridized oligos, a polymerase is added to extent the miRNA-specific oligos. Oligos are only extended if their 3’ bases are complementary to the cognate sequence in the cDNA template.

A PCR-based universal amplification of the extended miRNA specific primers is then performed, creating fluorescently labeled products. The labeled PCR products correspond to specific original miRNAs in the RNA sample. After PCR amplification the single-stranded PCR products are prepared for hybridization to the SAM. PCR products were hybridized for 16 hours to the beads on the arrays containing complementary address sequences. After hybridization signal intensities at each address location were measured using Illumina BeadArray Reader 500× (Illumina, CA). The intensities of the signals correspond to the quantity of the respective miRNA in the original sample.

Statistical and Bioinformatics Analysis

Raw data extraction of miRNA microarrays was performed with Illumina Beadstudio 3.1.1.0 software using the Beadstudio Gene Expression Analysis Module 3.1.8. All further analysis was performed in R statistical software (version 2.8.0) using Bioconductor packages. Prior analysis data quality assessment was performed, and samples with lower overall intensity distributions and decreased number of miRNA transcripts detected as present were excluded from further analysis. For further analysis we used quantile normalization implemented in the Bioconductor affy package.

Variable miRNAs were defined by a coefficient of variation (SD/mean) between 0.5 and 10. Determination of present calls was based on the detection P value assessed by Beadstudio software; a miRNA transcript was called present if the detection P value was <0.05. Otherwise the miRNA transcript was called absent. Differentially expressed miRNAs were selected using a fold-change/P value filter with the following criteria: Only P values smaller than 0.05 and an expression change higher than twofold and a difference between mean intensity signals greater 100 were considered statistically significant for further analysis. The Benjamini–Hochberg method was used to adjust the raw P values to control the false discovery rate. The fold-change was calculated by dividing the mean intensity of the miRNAs in one group by that in the other group. If this number was less than one, the negative reciprocal was used.

Hierarchical cluster analysis was performed using the hcluster method in R. Before clustering, the data were log2 transformed. Distances of the samples were calculated using Pearson correlation, and clusters were formed by taking the average of each cluster. Principle component analysis was performed using the pcurve package in R. When visualizing principle component analysis results, the first three principal components (coordinates) were z-transformed (mean, 0, SD = 1) and subsequently plotted in three dimensions.

Validation of miRNA Expression Results

Quantitative (q) PCR analysis of a selected number of miRNA targets was performed on the six aforementioned blood samples from healthy donors. Three RNA isolation approaches were compared: total RNA, enriched small RNA, and PAXgene-isolated RNA. Twelve miRNAs were selected (hsa-miR-100, 125a, 125b, 135a, 146a, 150, 17-3p, 221, 26a, 31, 93, and 328), and data were produced as described previously using those RNA samples that were also analyzed in array based miRNA profiling. Absolute association of normalized miRNA array expression intensities (log10) versus the negative cycle threshold (Ct) value was explored via Spearman’s correlation coefficient.

Results

High Technical Reproducibility of the miRNA Assay in Peripheral Blood

Before analyzing miRNA expression profiles in peripheral blood we addressed technical aspects of the newly introduced microarray technology. Therefore, the technical reproducibility of miRNA profiles was evaluated within and between different SAM devices, which allow the assessment of 735 miRNA profiles of 96 samples in parallel. First, RNA samples derived from PBMCs of 11 different healthy donors (biological replicates) were analyzed in triplicates on one SAM (intra-SAM reproducibility), and in the
The intra- and inter-SAM reproducibility of the replicates was estimated by calculating the Pearson correlations ($r^2$) for all pair-wise combinations of individual miRNA profiles within a given sample. The overall mean correlation coefficient in intrareproducibility was 0.9933 ± 0.0066. For inter-SAM analysis the overall mean correlation coefficient was 0.9880 ± 0.0069. Both calculated $r^2$-values are displayed in Figure 1A. Taken together, intra- and inter-SAM reproducibility of the miRNA microarray assay was very high. To assess whether the variability in miRNA expression among the 29 healthy subjects is associated with specific individual parameters, we correlated the expression values of all miRNAs with age and gender (see Supplemental Table S1 at http://jmd.amjpathol.org). Only one miRNA (hsa-miR-126) had a significant moderate correlation with age ($r^2 = 0.69$), and none was significantly correlated with gender.

To test the lowest amount of total RNA derived from PBMCs, which still yields reliable results in the miRNA assay, a titration experiment was performed using a broad range of input amounts of total RNA (2, 12.5, 25, 50, 100, 200, 500 ng) from three healthy individuals, which were tested in triplicates. Analysis of variance was performed to assess the reproducibility of miRNA microarray data in the titration experiments by comparing all RNA input amounts below 500 ng against the 500 ng RNA reference, and the correlation within each biological replicate were calculated. As demonstrated in Figure 1B, correlations remained relatively constant when using 100 to 500 ng total RNA (mean $r^2 = 0.97$) indicating that the input of 100 ng total RNA still leads to reliable results. Furthermore, data were still reproducible for replicates with 2 ng total RNA ($r^2 > 0.9$). When comparing all input amounts of 2, 12.5, 25, 50, 100, and 200 ng to the reference of 500 ng, there was a statistically significant difference ($t$ test $P$ value <0.05) for the samples with 50 ng or less input amount indicating that less than 100 ng total RNA is not sufficient to produce reliable results in peripheral blood derived samples.

**miRNA Assay Specificity of Blood-Derived Total versus Enriched LMW RNA miRNA Expression Profiles**

Next, we were interested in whether the presence of other RNA molecules such as mRNA including miRNA precursor RNA or ribosomal RNA had any influence on the blood expression profiling of miRNAs. To address this question, we compared PBMCs derived miRNA profiles of total RNA to enriched LMW RNA profiles from six healthy individuals. Therefore, fractions of total RNA as well as of less abundant LMW-enriched RNA below 200 bp were extracted. In contrast to the total RNA fraction, pri-miRNA sequences as well as miRNAs and ribosomal RNAs should be depleted in the LMW RNA fraction. The mean overall correlation coefficient between samples for total RNA was 0.9907 ± 0.0043 and for enriched LMW-RNA 0.9786 ± 0.0113, indicating a high similarity between the samples and showing that LMW RNA enrichment procedure introduces only little variation (data not shown).
Next the miRNA expression profiles of total and enriched LMW-RNA were compared. By statistically testing for differentially expressed miRNAs, 134 miRNAs of 735 (18%) were identified to be significantly changed in the process of LMW RNA enrichment (fold-change \(H_1 > 2\), total difference in mean signal intensity between both groups \(H_1\) and Benjamini–Hochberg adjusted \(P\) value \(0.05\)). In total 60 transcripts exhibited diminished signal intensities in enriched LMW-RNA and 74 transcripts had increased signal intensities. Thereof, 24 transcripts were predicted miRNA sequences and 110 were known miRNAs. Supplemental Table S2 at http://jmd.amipathol.org summarizes these transcripts. Unsupervised classification analysis, hierarchical clustering, and principal component analysis based on the most variable transcripts in this dataset demonstrate a clear separation of the expression profile between total and enriched small RNA as shown in Figure 2, A and B.

Taken together, there is a significant difference in the expression profiles between total and enriched LMW RNA, indicating that the miRNA assay is sensitive to size fractionation.

**Effect of Cryopreservation of PBMCs on miRNA Expression Profiles in Blood Samples of Healthy Individuals**

Based on our experience with gene expression data, we have clear evidence that sample storage and preparation techniques influence gene expression results.\(^2\) Because many tissues and cells from clinical samples are often stored for long time periods in liquid nitrogen (i.e., to allow retrospective gene or miRNA expression analysis), it is important to know whether expression profiles remain stable or undergo in vitro changes. We therefore assessed whether the storage of viable cells in liquid nitrogen has any impact on the stability of miRNA transcripts. For this purpose, miRNA expression profiles derived from total RNA obtained from fresh or frozen PBMCs (see Materials and Methods) of 29 healthy individuals were compared.

Although the mean overall Pearson correlation coefficient for the sample-wise comparison between fresh and frozen PBMCs was 0.9291 ± 0.0292, the hierarchical cluster analysis clearly demonstrated an incisive effect.
on miRNA expression profiles, resulting in a clear separation of fresh PBMCs from frozen specimens (Figure 3A). None of the related sample pairs clustered together or were grouped together, indicating that fresh and frozen cells cannot be compared directly.

Comparison analysis revealed 38 miRNA transcripts (\(=5.17\%\)) that significantly differ (fold-change \(> \pm 2\), total difference in mean signal intensity between both groups \(>100\) and Benjamini–Hochberg adjusted \(P\) value \(<0.05\)) between both groups with 21 transcripts exhibiting diminished signal intensities in frozen PBMCs samples and 17 transcripts with increased signal intensities including, e.g., miRNAs 132 and let-7b, which were described as clinically relevant earlier.\(^{5,9,41}\) These transcripts are summarized in Supplemental Table S3 at http://jmd.amijpathol.org. Evaluating the variability of miRNA expression data in both groups revealed an overall higher variability in the freshly prepared PBMC group (Figure 3B), indicating that the freezing procedure might affect miRNA transcripts responsible for interindividual variation in healthy subjects.

Comparison of miRNA Expression Profiles Derived from PBMCs and From Whole Blood Samples

To determine the effect of different blood cell populations and their influence on miRNA expression profiling, we compared RNA derived from PBMCs to RNA from whole blood samples. Therefore, blood samples from six donors were collected into either CPT tubes followed by PBMC separation and total RNA isolation using TRIZOL or were collected into PAXgene Blood RNA Tubes followed by direct RNA extraction using the newly introduced PreAnalytiX’s PAXgene Blood miRNA \(\beta\) Version kit.

There was no relevant difference in the amount and quality of the obtained RNA. When assessing miRNA microarray quality both RNA isolation techniques revealed comparable results. This is demonstrated by low variances in the signal intensity distributions and overall percent present calls (Figure 4A). No statistically significant difference in mean expression intensity or detection rate was seen. The same is true for intragroup correlation being \(0.9639 \pm 0.02\) for the whole blood derived RNA and \(0.9796 \pm 0.02\) for RNA from PBMCs. When comparing variance derived from PBMCs and whole blood samples we observed increased variance in the whole blood samples (\(t\) test \(P\) value \(<0.05\) probably attributable to the increased heterogeneity of cell types in whole blood compared with the PBMC fraction. The intragroup variance is displayed in Figure 4B. The clear differences between whole blood versus PBMC-derived profiles led to a total of 158 miRNAs (21.55\%\%) differentially expressed miRNAs (\(P\) value \(<0.05\), fold-change \(> \pm 2\)) and a mean \(I^2\) between sources of 0.7889 \(\pm 0.180\). Of these 158 miRNAs, 92 are up- and 66 are down-regulated in whole blood–derived RNA samples. Among these less abundant miRNAs are two members of the let-7 family (let-7f and let-7g) and mir-21, which have been shown to be involved in different disease areas.\(^{37–39}\) A summary of the 158 differentially expressed miRNAs is provided in Supplemental Table S4 at http://jmd.amijpathol.org.

qPCR Validation of miRNA Array Data

To verify the accuracy of this bead-based technology and to validate miRNA expression, qPCR data were explored for 12 miRNAs for blood samples derived from the six aforementioned healthy donors. Three RNA isolation approaches were chosen: total RNA, enriched small RNA, and PAXgene RNA. In all three comparisons absolute normalized expression values from the miRNA array were highly correlated to qPCR Ct values as demonstrated in Figure 5. A–C with Spearman’s correlation \(r^2\) values of 0.9597 for total RNA samples, 0.8346 for enriched small RNA samples, and 0.8873 for PAXgene RNA samples.
**Discussion**

We have studied the performance of a miRNA expression profiling microarray platform when assessing samples derived from peripheral blood in healthy subjects. More importantly, we addressed reproducibility and sample handling issues as well as the influence of different blood-based RNA extraction methods.

To study the reproducibility of data generated on this new miRNA array platform we evaluated several technical replicates derived from peripheral blood samples of healthy subjects. Before data analysis, we checked the quality of every miRNA array and removed samples with lower technical quality from further processing. Next we compared different normalization methods and finally used quantile normalization, because this method showed the highest overall correlation between samples and the lowest variance among replicated samples. These results are in line with the results derived from the study of Rao et al.36 A high reproducibility of miRNA expression data was estimated by calculating correlation coefficients of technical replicates on the same as well as on different SAM devices. All technical replicates analyzed revealed correlation coefficients >0.98 indicating high reproducibility and reliability of this miRNA microarray assay. Moreover, variability within the miRNA expression profiles was not correlated with gender or (except one miRNA) with age. We thus conclude that the variability within the gene expression profiles is not predominantly influenced by these conditions. A high sensitivity of the miRNA assay method was shown for tissue samples and cell lines by Chen et al.,31 and we extend these findings demonstrating that highly reproducible miRNA expression profiles are generated with 100 to 200 ng total RNA input from PBMCs and stabilized whole blood.

In contrast to mRNA profiling technologies, miRNA profiling must take into account the difference between mature miRNAs and their precursors. The interference of signals from pri-miRNAs and other larger RNAs exhibiting miRNA target sequences has therefore to be avoided.40-41 Chen et al.31 showed that the method evaluated in this study generates similar expression profiles with total RNA and enriched LMW-RNA having a correlation greater than 0.97 using a prostate adenocarcinoma cell line (PC-3). The data of our study clearly indicate that assay results are different if using total RNA or enriched LMW-RNA derived from peripheral blood. However, reproducibility and correlation were very high if results were compared between assays using the same preprocessing procedures ($r^2$>0.99), showing that the enrichment procedure itself did not add variation to the measurement. Thus, enrichment of LMW-RNA can, on one hand, lower cross-hybridization through inactive precursors of the miRNAs present in total RNA or through additional mRNA interference. On the other hand, this procedure might also lead to a biased composition of mature miRNAs lacking, for example, less abundant active miRNA sequences. Both phenomena could account for the variations we observed when using RNA enrichment. However, because total RNA as well as enriched LMW-RNA thereof give reliable and reproducible results, both methods should be valid for diagnostic purposes when taking into account its specific limitations.

Cryopreservation of clinical specimens, including PBMCs, is a commonly used technique in many clinical trials. In particular for multicenter studies, the performance of batch testing of harvested frozen samples in a central diagnostic unit is often preferred on the independent analysis of fresh samples at different study sites. However, cryopreservation is associated with adverse effects on subsequent functional studies in comparison with those performed with freshly isolated cells (e.g., it has been described recently that cryopreservation of PBMCs results in loss of T cell responses following long-term cryopreservation42). Cryopreservation also seems to have an influence on dendritic cells (DCs) monitored by affecting the proportion of myeloid DCs and plasmacytoid DCs and expression levels of DC-associated genes.43 Furthermore, it can affect cell viability.44,45 Both the freezing process as such as well as the addition of DMSO enabling the asservation of viable cells could account for these alterations, because DMSO is already known to induce changes to the transcriptome under certain conditions.46 Here we estimated the influence of cryopreservation of isolated PBMCs on miRNA expression profiles by comparing cryopreserved PBMCs with their matched counterparts directly lysed after isolation. We clearly demonstrated that the miRNA profiles of cryopreserved PBMC samples were not comparable with freshly isolated PBMCs, similar to findings obtained in mRNA expression studies.2,47 One interesting finding is the increase in signal intensity of miR-132 and let-7b in samples prepared from frozen PBMC samples in com-
parison with freshly isolated PBMCs. MiR-132 was recently identified as up-regulated in malignant B-cells derived from B-CLL patients in comparison with B-cells derived from healthy individuals,11 and members of the let-7 family are known to regulate transcripts of the proto-oncogene RAS, which are down-regulated in lung cancer specimen.48 The fact that the expression of these apparently informative miRNAs in diseased tissues seems to be affected by simple sample preparation issues underlines the necessity of uniformly prepared samples for miRNA analysis. A careful and uniform selection of sample material therefore needs to be assured within a study, and attention needs to be paid to those transcripts that are affected by sample handling procedures.

In a clinical setting peripheral blood is the most widely used tissue for disease monitoring. If miRNA expression profiling will become a routine tool for diagnostic and prognostic clinical studies, it is crucial to understand the differences by using either whole blood samples or isolated PBMCs. For gene expression studies of whole blood samples, RNA derived from PAXgene Blood RNA tubes is clinically the most suitable methodology.2,49–51 because of immediate stabilization of original expression profiles in blood cells. Moreover according to the manufacturers’ protocol blood-filled PAXgene tubes can be stored for up to 50 month at −80°C without alteration of the RNA composition. We compared miRNA expression profiles derived from PBMCs using TRIZOL isolation and from whole blood using a PAXgene Blood miRNA Kit β Version extraction kit. Most importantly, we assessed the newly introduced PAXgene isolation method as a robust technique for total RNA including miRNA extraction of blood samples whose RNA quality is comparable with RNA obtained from PBMCs using TRIZOL. Analysis of amount of present miRNAs, overall signal intensity, and intragroup correlation gave similar results. Akin to mRNA expression profiling, whole blood–derived miRNA profiles exhibit higher variance and results in miRNAs significantly differentially expressed in comparison with the PBMC-derived profile. Among the miRNAs that are more abundant in PBMCs compared with whole blood, the altered expression of two members of the let-7 family (let-7f and let-7g) and miR-2137,38 demonstrated again that sample handling is crucial when analyzing expression profiles of potentially clinically relevant miRNA genes. As a higher amount of the differentially expressed miRNAs is up-regulated in PBMCs, those miRNAs could have emerged because of different regulation processes during the PBMC isolation procedure. Alternatively, the additional presence of miRNA transcripts derived from red blood cells,13 granulocytes, as well as from serum in whole blood RNA samples might lead to different expression profiles when comparing to PBMCs. These miRNAs as well as transcripts that are sequestered via microvesicles13 are of course lost if only analyzing isolated PBMCs. Therefore, using PBMCs might lead to misleading results in diagnostic or prognostic assays.

Finally the expression of 12 miRNAs was determined by qPCR as another established expression technology. Good correlation coefficients between miRNA array expression levels and qPCR values were assessed for total RNA and enriched small RNA as previously reported.31,52 PAXgene samples performed similarly well. We therefore conclude that the bead array platform revealed reliable results compared with the hitherto used qPCR method as gold standard for miRNA profiling.

Taken together, we present clear evidence that highly reproducible and reliable miRNA profiles of primary human peripheral mononuclear cells as well as of whole blood samples are obtained by the miRNA bead array technology. We clearly demonstrate that sample handling and the choice of either PBMCs or whole blood is a rather critical issue when assessing miRNA profiles. Furthermore, we evaluated that the assay monitors different expression profiles when RNA size fractionation is performed. This comprehensive dataset of miRNA profiles derived from peripheral blood of healthy individuals might serve as a valuable resource for future steps toward the establishment of a comprehensive global miRNA profile of human peripheral blood for diagnostic as well as prognostic purposes.

Acknowledgments

We are grateful to all blood donors for donating blood for this study. We thank Mirela Stecki, Michael Kraut, and Julia Claasen for excellent technical assistance and Tanya Boyaniwski from Illumina for helpful discussions throughout the project.

References


Blood Based miRNA Expression Profiles 9 JMD May 2010, Vol. 12, No. 3